Same breakdowns, in text you can skim, copy a line out of, and come back to six months later. Each one carries the video it came from and the sources behind it.
An independent analysis of more than six thousand samples found four in ten failed a basic purity or abundance standard. That is not an evidence problem. It is a manufacturing one.
It borrows the same target as an injected treatment, and one small trial found a real result. But at almost double the size limit for crossing skin on its own, Argireline runs into a wall before it ever reaches that target.
A synthetic fragment of a stress hormone, a solid rodent mechanism, and a human evidence base thin enough to fit in two paragraphs — here is what the paperwork on Semax actually supports, and what it still does not.
A real, decades-old drug with approvals abroad — and every trial ran in people who were already ill. Never once in anyone healthy.
Four systems can produce or handle a peptide. Each leaves a different paper trail, and one is built to leave nothing to check.
It arrives in a vial labelled peptide, and the sequence runs to 1,012 amino acids with seven glycosylation sites. That is not a long peptide. It is a different manufacturing category.
Same two amino acids, same formula, same mass — and two separate national drug registrations pointing opposite ways. The variable a purity number was never built to see.
A peptide named after delta sleep, with no confirmed mechanism and trials that argue with each other. Watch the effect shrink as the study design tightens.
A melted ice pack is not a verdict. How the pharmaceutical industry actually measures heat exposure — and why the thing doing the damage is probably in your kitchen.
Cloudy, floaters, colour, smell — the four checks everyone runs. What visual inspection can and cannot detect, according to the people who do it professionally.
It is 28, not 30, and it is a sterility rule for a punctured vial — not a statement about your molecule. Where the number really comes from.
Before you write a compound off, rule out the five execution failures that explain most “it did nothing” reports — including the one that means your vial was already finished before it reached your fridge.
Ranked not by hype but by how much real human evidence holds each one up. One was beaten by a saline injection, one has never been tested in a person, and the most effective thing on the list turns out not to be a peptide.
A three-amino-acid scrap of the tanning hormone that quiets inflammation at tiny concentrations, rides a transporter that opens wider exactly where the damage is, and moonlights as an antibiotic. Now the part the hype skips.
A triple agonist really did produce the biggest weight-loss figure this drug class has ever recorded. But that number is the top dose, after two years, with a real dropout rate — and a third of what the scale gives back isn’t fat.
Milligrams, millilitres and syringe units are three scales for one vial — which is the whole reason the maths feels hard. Here is the ratio, the trap that doubles a dose without moving the plunger, and why degradation is the real constraint.
The committee overruled the FDA’s scientific reviewers on six of seven peptides — and rejected the seventh. Inside the arguments, the one rejection that proves it wasn’t a rubber stamp, and why a vote is not a rule.
Bremelanotide is one of the very few peptides carrying a real FDA label, which makes it the rare case where the hype can be checked directly against the trial data.
“Research use only” is not a quality standard — it is the mechanism that moves the entire quality function from an inspected factory onto the buyer.
A Certificate of Analysis is only as good as your ability to read it. Here’s the two-number test, the forgery tells, and why 99% purity can still mean you got shorted.
The FDA's compounding advisory committee backed six of seven peptides on 23–24 July 2026 — against its own reviewers. Here is what that vote does, and what it very much does not do.
The withdrawal trials predicted post-GLP-1 rebound before anyone posted about it. Here is the real mechanism, the honest numbers, and why the boring fundamentals beat the peptide add-ons.
The copper peptide and the telomere peptide, graded honestly — real mechanisms, a database lookup masquerading as 4,000 effects, and a Russian trial record nobody has replicated.
Melanotan II, argireline, Matrixyl, GHK-Cu and the CJC-1295 plus ipamorelin stack, ranked on what has actually been measured rather than what gets claimed.
TB-500 is not thymosin beta-4 — it's a seven-residue fragment with no human trials of its own, and a 2024 study suggests it may only work after your enzymes chop it up.
Five gym-performance peptides ranked by what the evidence actually supports — including the hyperplasia claim I got wrong the first time round.
MOTS-c and SS-31 target the mitochondria rather than your appetite — a beautiful mechanism with a much shakier evidence base than the hype admits.
BPC-157 has spectacular animal data and almost no human data — here is the mechanism, the evidence, and the honest verdict as of late July 2026.
Join the list and all three free guides come with it — the 12-Point COA Quick-Check card, the Peptide Storage Reality Check, and How to Read a Peptide Study Like an Engineer. After that it’s a short note when something new lands, and nothing else.
I’ve just sent a confirmation email to your address. Click the link in it and all three free guides land in your inbox straight away.
It may go to junk or spam. If it isn’t in your inbox within a minute or two, check your junk/spam folder — and Gmail’s Promotions tab. Mark it “not spam” so the guides actually reach you.
Nothing arrives at all? Email info@peptidecorner.net and I’ll send them over by hand.
